Articles, chapters, and work in progress

Armstrong, S. B., Levin, A. W., Sepeda, N. D., Shaub, H., Hunter, T., Douglas, A., Lancelotta, R., & Davis, A. K. (2026). Safety, feasibility, and preliminary clinical outcomes of psilocybin-assisted therapy for veterans with severe, treatment-resistant PTSD: An open-label pilot clinical trial. Communications Medicine, 6, 411. doi:10.1038/s43856-026-01767-4

Gaughan, S. J., Sevelius, J. M., Lancelotta, R., Anderson, K. D., Davis, A. K., Wootton, A. R., Krantz, D., & James, J. E. (2026). Transgender and gender-expansive psychedelic users' concerns about colonization, racism, and medicalization in western psychedelic science. Psychedelics, 3, 100011. doi:10.1016/j.psyche.2026.100011

Lancelotta, R. L., Nagib, P. B., Armstrong, S. B., Levin, A. W., & Davis, A. K. (2026). Development and assessment of a psychedelic-assisted therapy music playlist for clinical trials: Theory, intentionality, and metrics. Journal of Psychedelic Studies. doi:10.1556/2054.2026.00462

Armstrong, S. B., DellaCrosse, M., Fuentes-Balderrama, J., Lancelotta, R., & Davis, A. K. (2025). Self-reported improvement in depression, anxiety, and substance use in Spanish-speakers after a memorable psychedelic experience. Psychedelics, 2, 100006. doi:10.1016/j.psyche.2025.100006

DellaCrosse, M., Gilead, S., Lancelotta, R., Ortiz Bernal, A. M., Timmermann, C., & Davis, A. K. (2025). Qualitative insights into psilocybin and LSD experiences: Enhanced connection and emotion processing reported by Spanish-speaking survey respondents. Psychedelics, 2, 100004. doi:10.1016/j.psyche.2025.100004

Ortiz Bernal, A. M., Raison, C. L., Lancelotta, R. L., Timmermann, C., Sepeda, N. D., & Davis, A. K. (2025). Reactivations associated with the use of 5-MeO-DMT among Spanish-speaking individuals: Prevalence, predictors, and emotional valence. Journal of Psychoactive Drugs. doi:10.1080/02791072.2025.2577305

Lancelotta, R., DellaCrosse, M., Quinn, D., Saniyah, S., Saniyah, M., Gukasyan, N., Narayan, S., Nikolaidis, A., Sevelius, J., & Davis, A. K. (2025). Exploring self-reported effects of naturalistic psychedelic use among gender and sexual minorities: A quantitative survey study. Journal of Psychoactive Drugs. doi:10.1080/02791072.2025.2520224

Gaughan, S. J., Wootton, A. R., Krantz, D., Davis, A. K., James, J. E., Rinaldi-Rose, R., Lancelotta, R., & Sevelius, J. M. (2025). Naturalistic psychedelic experiences and gender-based self-acceptance in transgender and gender-expansive people. International Journal of Transgender Health. doi:10.1080/26895269.2025.2478112

Levin, A. W., Lancelotta, R., Sepeda, N. D., Gukasyan, N., Nayak, S., Wagener, T. L., Barrett, F. S., Griffiths, R. R., & Davis, A. K. (2024). The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder. PLOS ONE, 19(3), e0300501. doi:10.1371/journal.pone.0300501

Nikolaidis, A., Lancelotta, R., Gukasyan, N., Griffiths, R. R., Barrett, F. S., & Davis, A. K. (2023). Subtypes of the psychedelic experience have reproducible and predictable effects on depression and anxiety symptoms. Journal of Affective Disorders, 324, 239–249. doi:10.1016/j.jad.2022.12.042

Davis, A. K., Levin, A. W., Nagib, P. B., Armstrong, S. B., & Lancelotta, R. L. (2023). Study protocol of an open-label proof-of-concept trial examining the safety and clinical efficacy of psilocybin-assisted therapy for veterans with PTSD. BMJ Open, 13(5), e068884. doi:10.1136/bmjopen-2022-068884

Davis, A. K., Timmermann, C., Ortiz Bernal, A. M., Lancelotta, R., Nayak, S., Sepeda, N. D., Nikolaidis, A., & Griffiths, R. R. (2023). Translation and initial psychometric evaluation of Spanish versions of three psychedelic acute effects measures: Mystical, challenging, and insight experiences. Journal of Psychoactive Drugs. doi:10.1080/02791072.2023.2232379

Lancelotta, R. (2022). 5-MeO-DMT has not been found in traditional ayahuasca preparations and the combination of 5-MeO-DMT with MAOIs is dangerous. Human Psychopharmacology: Clinical and Experimental, 37(3), e2839. doi:10.1002/hup.2839

Reckweg, J. T., Uthaug, M. V., Szabo, A., Davis, A. K., Lancelotta, R., Mason, N. L., & Ramaekers, J. G. (2022). The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT). Journal of Neurochemistry. doi:10.1111/jnc.15587

Ortiz Bernal, A. M., Raison, C. L., Lancelotta, R. L., & Davis, A. K. (2022). Reactivations after 5-methoxy-N,N-dimethyltryptamine use in naturalistic settings: An initial exploratory analysis of the phenomenon's predictors and its emotional valence. Frontiers in Psychiatry, 13. doi:10.3389/fpsyt.2022.1049643

Agin-Liebes, G., Haas, T. F., Lancelotta, R., Uthaug, M. V., Ramaekers, J. G., & Davis, A. K. (2021). Naturalistic use of mescaline is associated with self-reported psychiatric improvements and enduring positive life changes. ACS Pharmacology & Translational Science. doi:10.1021/acsptsci.1c00018

Uthaug, M. V., Davis, A. K., Haas, T. F., Davis, D., Dolan, S. B., Lancelotta, R., Timmermann, C., & Ramaekers, J. G. (2021). The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects. Journal of Psychopharmacology. doi:10.1177/02698811211013583

Uthaug, M. V., Lancelotta, R., Szabo, A., Davis, A. K., Riba, J., & Ramaekers, J. G. (2020). Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: Effects on salivary IL-6, cortisol levels, affect, and non-judgment. Psychopharmacology, 237(3), 773–785. doi:10.1007/s00213-019-05414-w

Lancelotta, R. L., & Davis, A. K. (2020). Use of benefit enhancement strategies among 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) users: Associations with mystical, challenging, and enduring effects. Journal of Psychoactive Drugs. doi:10.1080/02791072.2020.1737763

Uthaug, M. V., Lancelotta, R., Ortiz Bernal, A. M., Davis, A. K., & Ramaekers, J. G. (2020). A comparison of reactivation experiences following vaporization and intramuscular injection (IM) of synthetic 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting. Journal of Psychedelic Studies. doi:10.1556/2054.2020.00123

Luoma, J. B., Chwyl, C., Bathje, G. J., Davis, A. K., & Lancelotta, R. (2020). A meta-analysis of placebo-controlled trials of psychedelic-assisted therapy. Journal of Psychoactive Drugs. doi:10.1080/02791072.2020.1769878

Uthaug, M. V., Lancelotta, R., van Oorsouw, K., Kuypers, K., Mason, N. L., Rak, J., Šuláková, A., Jurok, R., Maryška, M., Kuchař, M., Páleníček, T., Riba, J., & Ramaekers, J. G. (2019). A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms. Psychopharmacology. doi:10.1007/s00213-019-05236-w

Sepeda, N. D., Clifton, J. M., Doyle, L. Y., Lancelotta, R., Griffiths, R. R., & Davis, A. K. (2019). Inhaled 5-methoxy-N,N-dimethyltryptamine: Supportive context associated with positive acute and enduring effects. Journal of Psychedelic Studies. doi:10.1556/2054.2019.033

Davis, A. K., Barsuglia, J. P., Lancelotta, R., Grant, R., & Renn, E. (2018). The epidemiology of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption. Journal of Psychopharmacology. doi:10.1177/0269881118769063

Davis, A. K., So, S., Lancelotta, R., Barsuglia, J., & Griffiths, R. (2018). 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. The American Journal of Drug and Alcohol Abuse. doi:10.1080/00952990.2018.1545024

Barsuglia, J., Davis, A. K., Palmer, R., Lancelotta, R., Windham-Herman, A., Peterson, K., Polanco, M., Grant, M., & Griffiths, R. (2018). Intensity of mystical experiences occasioned by 5-MeO-DMT and comparison with a prior psilocybin study. Frontiers in Psychology. doi:10.3389/fpsyg.2018.02459

Lancelotta, R., & Davis, A. K. (2021). Therapeutic potential of fast-acting synthetic tryptamines. In C. S. Grob & J. Grigsby (Eds.), Handbook of Medical Hallucinogens. The Guilford Press.

Esposito, M., Ortiz Bernal, A. M., Davis, A. K., & Lancelotta, R. (2026). 5-MeO-DMT use in humans: A scoping review of peer-reviewed research. PsyArXiv. doi:10.31234/osf.io/g8phu_v1

Davis, A. K., Wagener, T., Shields, P., Andersen, B., Armstrong, S., Levin, A., Sloan, R., Pham, M., Reisinger, S., Lancelotta, R., Shaub, H., Douglas, A., Hunter, T., Cassidy, E., Ellis, S., & Kusiak, E. Study protocol for an open-label Phase II proof-of-concept trial exploring the safety, acceptability, and efficacy of psilocybin-assisted therapy among non-small cell lung cancer patients with major depressive disorder. PLOS ONE.